




FIG. 1

	Baseline		12 month		Treatment Effect* (n = 26)	P Value*
	Tesamorelin (n = 31)	Placebo (n = 30)	Tesamorelin (n = 21)	Placebo (n = 26)		
Liver Endpoints						
Primary						
Hepatic fat, absolute change, %	12.9 ± 7.7	14.7 ± 9.0	10.0 ± 7.9	14.5 ± 9.0	-4.1 (-7.5, -0.7)	0.02
Hepatic fat, relative change, %	N/A	N/A	-32 ± 54	5 ± 42	-37 (-67, -7)	0.02
Resolution at 12 months, %	N/A	N/A	35	4	31	0.007
Secondary						
ALT, U/L	33 ± 25	26 ± 18	26 ± 16	34 ± 29	-7 (-15, 1)	0.09
GGT, U/L	55 ± 54	65 ± 76	45 ± 35	67 ± 86	-19 (-43, 4)	0.10
Adipose tissue						
VAT, cm²	232 ± 91	250 ± 104	216 ± 108	257 ± 112	-35 (-66, -4)	0.03
SAT, cm²	290 ± 164	333 ± 156	324 ± 187	352 ± 165	11 (-19, 41)	0.46
BMI, kg/m²	30.1 ± 6.0	32.9 ± 6.2	31.3 ± 7.3	33.5 ± 6.7	0.3 (-0.3, 0.9)	0.37
Waist, cm	107 ± 15	114 ± 12	109 ± 17	116 ± 14	-1 (-5, 3)	0.59
Total body fat (kg)	30.3 ± 10.5	34.4 ± 12.0	32.5 ± 12.3	36.7 ± 12.5	-0.7 (-3.3, 2.0)	0.61
Total lean body mass (kg)**	57.2 ± 10.2	63.8 ± 10.6	58.1 ± 10.7	63.9 ± 10.4	1.9 (-0.0, 3.8)	0.05
Metabolic Indices						
IGF-1, ng/mL	132 ± 43	115 ± 43	238 ± 87	116 ± 45	117 (76, 157)	< 0.0001
Triglycerides, mg/dL	151 ± 84	128 ± 46	141 ± 70	126 ± 39	23 (-7, 53)	0.12
HDL-C, mg/dL	47 ± 13	45 ± 11	51 ± 12	44 ± 10	3 (-1, 6)	0.17
LDL-C, mg/dL	113 ± 36	102 ± 25	109 ± 37	105 ± 35	-5 (-21, 11)	0.54
CRP, mg/L	7.8 ± 9.9	4.2 ± 3.5	5.8 ± 6.4	6.0 ± 5.6	-4.7 (-9.2, -0.2)	0.04
Adiponectin, ng/mL	2042 ± 1450	1638 ± 875	2179 ± 1354	1233 ± 684	222 (-225, 669)	0.32
Glucose homeostasis						
Fasting glucose, mg/dL	96 ± 20	97 ± 16	98 ± 21	100 ± 14	4 (-5, 13)	0.40
HbA1c, %	5.7 ± 0.5	5.8 ± 0.5	5.9 ± 0.7	5.8 ± 0.6	0.2 (-0.1, 0.5)	0.29
CD4+ T-cells (cells/mm³)	733 ± 290	798 ± 260	731 ± 280	751 ± 270	17 (-60, 95)	0.65
CD8+ T-cells (cells/mm³)	865 ± 380	967 ± 374	775 ± 336	916 ± 378	-18 (-113, 77)	0.70
log HIV viral load (copies/mL)	0.34 ± 0.59	0.50 ± 0.74	0.53 ± 0.80	0.49 ± 0.70	0.18 (-0.25, 0.62)	0.41

FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D





FIG. 4A



Change in Fibrosis

FIG. 4B

**FIG. 5**